Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot pharmacokinetic study of aprepitant and dexamethasone interaction in children receiving chemotherapy
NL-OMON48783Active, not recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of aprepitant and dexamethasone in chemotherapy-induced nausea and vomiting (CINV), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Population pharmacokinetic model of dexamethasone and aprepitant. Started Mar 2019; status: active, not recruiting.
02
Drugs
aprepitantdexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON48783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48783.